ArticleInternational ophthalmology2025
Evaluation of tear and serum clusterin levels in thyroid ophthalmopathy patients.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate tear and serum clusterin levels in thyroid eye disease (TED) patients. MATERIAL AND
methodsThe study included 21 patients with Graves disease with TED, 20 patients with Graves disease without TED, and 21 healthy control subjects matched for sex and age. Clusterin and lysozyme C levels of tear and serum were detected using enzyme-linked immunosorbent assays. In addition, free triiodothyronine, free thyroxine, thyroid stimulating hormone (TSH), and autoantibody (anti thyroid peroxidase, anti thyroglobulin and TSH receptor antibody) levels were measured in all groups.
resultsThe mean concentrations of tear clusterin and lysozyme C levels were 15.99 ± 4.07 ng/mL and 54.54 ± 27.58 ng/mL in Graves patients with TED, 26,28 ± 15,98 ng/mL and 50,13 ± 46,59 ng/mL in Graves patients without TED, and 55,53 ± 45,99 ng/mL and 44,86 ± 27,42 ng/mL in control subjects, respectively. The mean concentrations of serum clusterin and lysozyme C levels were 23.15 ± 4.25 ng/mL and 93.14 ± 51.38 ng/mL in Graves patients with TED, and 26.73 ± 15.93 ng/mL and 74.22 ± 55.73 ng/mL in Graves patients without TED, and 27.47 ± 12.83 ng/mL and 76.13 ± 65.24 ng/mL in control subjects, respectively. The tear clusterin levels showed significant differences in Graves patients with and without TED than in the control group (p < 0.001). In Graves patients with TED group, tear clusterin levels were lower than in Graves patients without TED, however this difference was not statistically significant (p = 0.431). There was a statistically significant low-grade correlation between tear clusterin and clinical activity score, retraction, and Hertel measurements (range of r value: -0.299 and -0.279, and range of p values:0.024-0.034).
conclusionThe tear clusterin levels were decreased in Graves patients with and without TED. The results suggest that a local reduction in the amount of clusterin may play an important role in the pathogenesis of Graves disease and might be used as a local biomarker.
Indexed as
Identifiers
40119947What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.